143 related articles for article (PubMed ID: 18084955)
1. Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer.
Heeger S
Recent Results Cancer Res; 2008; 177():131-6. PubMed ID: 18084955
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
4. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
5. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract][Full Text] [Related]
6. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
8. EGFR targeting of solid tumors.
Rocha-Lima CM; Soares HP; Raez LE; Singal R
Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. EGFR-targeted therapies in the post-genomic era.
Xu MJ; Johnson DE; Grandis JR
Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
[TBL] [Abstract][Full Text] [Related]
12. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
Dhar A; Mehta S; Banerjee S; Dhar K; Dhar G; Sengupta K; Ray G; Banerjee SK; Campbell DR
Front Biosci; 2005 May; 10():1763-7. PubMed ID: 15769665
[TBL] [Abstract][Full Text] [Related]
14. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Strumberg D; Schultheis B; Scheulen ME; Hilger RA; Krauss J; Marschner N; Lordick F; Bach F; Reuter D; Edler L; Mross K
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):473-5. PubMed ID: 20557849
[No Abstract] [Full Text] [Related]
16. Target therapies in pancreatic carcinoma.
Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
19. [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer].
Larbouret C; Robert B; Teulon I; Azria D; Pèlegrin A
Med Sci (Paris); 2007 Oct; 23(10):800-3. PubMed ID: 17937885
[No Abstract] [Full Text] [Related]
20. The EGFR as a target for anticancer therapy--focus on cetuximab.
Baselga J
Eur J Cancer; 2001 Sep; 37 Suppl 4():S16-22. PubMed ID: 11597400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
